ANRO
ANRO
Positions held
Your positionsANRO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Alto Neuroscience Insider Sold Shares Worth $3,567,247, According to a Recent SEC Filing
2026-09-09 · Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-08-27 · Alto Neuroscience Promotes Nick Smith to President and CFO
2026-08-27 · Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
2026-08-16 · Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
2026-08-16 · Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
2026-08-16 · Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans
2026-08-14 · BofA Adjusts Price Target on Alto Neuroscience to $37 From $33
2026-08-13 · Wedbush Adjusts Price Target on Alto Neuroscience to $26 From $24, Keeps Neutral Rating
2026-08-12 · Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-13 · Alto Neuroscience Prices $100 Million Stock Offering
2026-07-13 · Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Price (daily)
Full chart · RSI · MACD · patterns